Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia

APMIS

Volumn 121, Issue 6, 2013, Pages 539-548

  Minárik, Gabriel ^a,b   Plank, Lukáš ^c   Lasabová, Zora ^c   Szemes, Tomáš ^b,d   Burjanivová, Tatiana ^c   Szépe, Peter ^c   Buzalková, Veronika ^c   Porubský, David ^d   Šufliarsky, Jozef ^e  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b Geneton Ltd ^*  (Slovakia)

^c University Teaching Hospital in Martin   (Slovakia)

^d Physics and Informatics   (Slovakia)

^e CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Ckit tyrosine kinase; Gastrointestinal stromal tumor; Gastrointestinal stromal tumors; PDGRFA; Slovak population

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLOVAKIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; EARLY DETECTION OF CANCER; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENETIC ASSOCIATION STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MITOTIC INDEX; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; PHENOTYPE; PREVALENCE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SLOVAKIA; YOUNG ADULT;

EID: 84878263424     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12019     Document Type: Article

References (40)

1. Rossle M, Hirschmann A, Diebold J. Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study. Eur J Cancer 2011;47:1305-11.
2. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011;104:865-73.
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
4. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34.
5. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
6. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
7. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64.
8. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.
9. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-13.
10. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
12. van Oosterom AT, Judson I, Verweij J, Stroobants S. Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
13. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7.
14. Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67(Suppl 1):S25-43.
15. Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CDM, Kazanovicz A, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 2004;22(Suppl 14):3001.
16. Blay JY. New paradigms in gastrointestinal stromal tumour management. Ann Oncol 2009;20(Suppl 1):i18-24.
17. Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7.
18. Kim EJ, Zalupski MM. Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib. J Surg Oncol 2011;104:901-6.
19. Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 2011;8:161-70.
20. Martin J, Poveda A, Llombart-Bosch A, Ramos R, Lopez-Guerrero JA. Garcia del Muro J, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190-8.
21. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008;21:476-84.
22. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
23. Ni S, Huang D, Chen X, Huang J, Kong Y, Xu Y, et al. c-kit gene mutation and CD117 expression in human anorectal melanomas. Hum Pathol 2011;43:801-7.
24. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22:1446-56.
25. Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, et al. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 2011;119:330-5.
26. Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2011;29:1765-72.
27. Kern A, Gorgens H, Dittert DD, Kruger S, Richter KK, Schackert HK, et al. Mutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary gastrointestinal stromal tumors (GISTs). J Surg Oncol 2011;104:59-65.
28. Braconi C, Bracci R, Bearzi I, Bianchi F, Costagliola A, Catalani R, et al. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol 2008;19:706-10.
29. Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67(Suppl 1):S15-24.
30. Tryggvason G, Hilmarsdottir B, Gunnarsson GH, Jonsson JJ, Jonasson JG, Magnusson MK. Tyrosine kinase mutations in gastrointestinal stromal tumors in a nation-wide study in Iceland. APMIS 2010;118:648-56.
31. Daniels M, Lurkin I, Pauli R, Erbstosser E, Hildebrandt U, Hellwig K, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 2011;312:43-54.
32. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
33. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1, 640 patients. J Clin Oncol 2010;28:1247-53.
34. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M. Mutations in gastrointestinal stromal tumors-a population-based study from Northern Norway. APMIS 2007;115:289-98.
35. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
36. Chen LL, Holden JA, Choi H, Zhu J, Wu EF, Jones KA, et al. Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. Mod Pathol 2008;21:826-36.
37. Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, Kordek R, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003;34:1306-12.
38. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-37.
39. Holden JA, Willmore-Payne C, Coppola D, Garrett CR, Layfield LJ. High-resolution melting amplicon analysis as a method to detect c-kit and platelet-derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors. Am J Clin Pathol 2007;128:230-8.
40. Battochio A, Mohammed S, Winthrop D, Lefresne S, Mulder K, Chu Q, et al. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort. Am J Clin Pathol 2010;133:149-55.